The EU-CARDIOPROTECTION COST Action (CA16225) is a pan-European research network of leading experts in experimental and clinical cardioprotection, whose overall aim is to improve the translation of novel experimental cardioprotective therapies into the clinical setting for patient benefit.
Translating Cardioprotection for Patient BenefitApril 17, 2019 | General
Acute myocardial infarction and the subsequent development of heart failure are among the leading causes of death and disability globally. The most effective treatment for limiting infarct size and preventing subsequent heart failure is timely interventional or surgical reperfusion, but even then, mortality and morbidity remain significant (1). Accordingly, new treatments are required, but the […]